Abhay Joshi's most recent trade in Revance Therapeutics Inc was a trade of 2,607 Common Stock done at an average price of $15.8 . Disclosure was reported to the exchange on March 15, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Revance Therapeutics Inc | Abhay Joshi | COO, President of R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.79 per share. | 15 Mar 2022 | 2,607 | 120,708 (0%) | 0% | 15.8 | 41,165 | Common Stock |
| Revance Therapeutics Inc | Abhay Joshi | COO, President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.35 per share. | 15 Feb 2022 | 2,902 | 123,315 (0%) | 0% | 13.4 | 38,742 | Common Stock |
| Revance Therapeutics Inc | Abhay Joshi | COO, President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.35 per share. | 15 Feb 2022 | 2,151 | 126,217 (0%) | 0% | 13.4 | 28,716 | Common Stock |
| Revance Therapeutics Inc | Abhay Joshi | COO, President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.73 per share. | 15 Mar 2021 | 1,354 | 128,368 (0%) | 0% | 27.7 | 37,546 | Common Stock |
| Revance Therapeutics Inc | Abhay Joshi | COO, President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.97 per share. | 15 Feb 2021 | 2,881 | 129,722 (0%) | 0% | 29.0 | 83,463 | Common Stock |
| Revance Therapeutics Inc | Abhay Joshi | COO, President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.97 per share. | 15 Feb 2021 | 1,967 | 132,603 (0%) | 0% | 29.0 | 56,984 | Common Stock |
| Revance Therapeutics Inc | Abhay Joshi | COO, President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 40,925 | 40,925 | - | - | Employee Stock Option (Right to Buy) | |
| Revance Therapeutics Inc | Abhay Joshi | COO, President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 22,620 | 134,570 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Abhay Joshi | COO, President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 17,500 | 119,332 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Abhay Joshi | COO, President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.14 per share. | 30 Sep 2020 | 7,382 | 111,950 (0%) | 0% | 25.1 | 185,583 | Common Stock |